[go: up one dir, main page]

WO1987000523A3 - Hydroxyalkylxanthines tertiaires, leur procede de fabrication, medicaments les contenant et leur utilisation - Google Patents

Hydroxyalkylxanthines tertiaires, leur procede de fabrication, medicaments les contenant et leur utilisation

Info

Publication number
WO1987000523A3
WO1987000523A3 PCT/EP1986/000401 EP8600401W WO8700523A3 WO 1987000523 A3 WO1987000523 A3 WO 1987000523A3 EP 8600401 W EP8600401 W EP 8600401W WO 8700523 A3 WO8700523 A3 WO 8700523A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
tertiary
manufacturing process
hydroxyalkylxanthines
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1986/000401
Other languages
German (de)
English (en)
Other versions
WO1987000523A2 (fr
Inventor
Ulrich Gebert
Ismahan Okyayuz-Baklouti
Werner Thorwart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019870700245A priority Critical patent/KR950001019B1/ko
Priority to JP61504113A priority patent/JPH0788382B2/ja
Priority to HU863670A priority patent/HU198486B/hu
Priority to AT86904158T priority patent/ATE53211T1/de
Priority to DE8686904158T priority patent/DE3671627D1/de
Priority to SU864355018A priority patent/RU2051918C1/ru
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of WO1987000523A2 publication Critical patent/WO1987000523A2/fr
Publication of WO1987000523A3 publication Critical patent/WO1987000523A3/fr
Priority to NO871111A priority patent/NO165803C/no
Priority to DK139287A priority patent/DK157867C/da
Priority to FI880174A priority patent/FI89921C/fi
Anticipated expiration legal-status Critical
Priority to LV930291A priority patent/LV5703A3/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Hydroxyalkylxanthines tertiaires de formule générale (I), caractérisés en ce qu'au moins un des résidus R1 et R3 représente un groupe hydroxyalkyle tertiaire de formule (Ia) dans laquelle R4 représente un groupe alkyle possédant jusqu'à 3 atomes de carbone et n un nombre entier compris entre 2 et 5; l'autre résidu éventuellement restant R1 ou R3 est un atome d'hydrogène ou bien un résidu d'hydrocarbure aliphatique R5 possédant jusqu'à 6 atomes de carbone, dont la chaîne carbonée peut être interrompue par 2 atomes d'oxygène au maximum ou bien être substituée par un groupe oxo ou deux groupes hydroxy au maximum, et R2 représente un groupe alkyle possédant de 1 à 4 atomes de carbone. Est également décrit un procédé de fabrication de ces composés, lesquels sont indiqués pour la fabrication de médicaments, en particulier pour des applications de prévention et/ou de traitement de troubles de l'irrigation cérébrale et/ou périphérique.
PCT/EP1986/000401 1985-07-19 1986-07-08 Hydroxyalkylxanthines tertiaires, leur procede de fabrication, medicaments les contenant et leur utilisation Ceased WO1987000523A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SU864355018A RU2051918C1 (ru) 1985-07-19 1986-07-08 Способ получения третичных оксиалкилксантинов
JP61504113A JPH0788382B2 (ja) 1985-07-19 1986-07-08 第三ヒドロキシアルキルキサンチン、それらの製造法及びそれを含有する治療剤
HU863670A HU198486B (en) 1985-07-19 1986-07-08 Process for producing tertiary hydroxy-alkyl-xanthines and pharmaceutical preparations containing such active agents
AT86904158T ATE53211T1 (de) 1985-07-19 1986-07-08 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
DE8686904158T DE3671627D1 (de) 1985-07-19 1986-07-08 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
KR1019870700245A KR950001019B1 (ko) 1985-07-19 1986-07-08 3급 하이드록시 알킬크산틴의 제조방법
NO871111A NO165803C (no) 1985-07-19 1987-03-18 Analogifremgangsmaate for fremstilling av terapeutisk aktive tertiaere hydroksyalkylxantiner.
DK139287A DK157867C (da) 1985-07-19 1987-03-18 Tertiaere hydroxyalkylxanthiner og deres anvendelse som laegemidler
FI880174A FI89921C (fi) 1985-07-19 1988-01-15 Foerfarande foer framstaellning av terapeutiskt anvaendbara tertiaera hydroxialkylxantiner
LV930291A LV5703A3 (lv) 1985-07-19 1993-05-05 Panemiens tresejo oksialkilksantinu iegusanai

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DEP3525801.2 1985-07-19

Publications (2)

Publication Number Publication Date
WO1987000523A2 WO1987000523A2 (fr) 1987-01-29
WO1987000523A3 true WO1987000523A3 (fr) 1987-02-26

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1986/000401 Ceased WO1987000523A2 (fr) 1985-07-19 1986-07-08 Hydroxyalkylxanthines tertiaires, leur procede de fabrication, medicaments les contenant et leur utilisation

Country Status (33)

Country Link
US (1) US4833146A (fr)
EP (1) EP0268585B1 (fr)
JP (1) JPH0788382B2 (fr)
KR (1) KR950001019B1 (fr)
CN (1) CN1026112C (fr)
AR (1) AR244689A1 (fr)
AT (1) ATE53211T1 (fr)
AU (1) AU588350B2 (fr)
BG (1) BG60767B2 (fr)
CA (1) CA1262248A (fr)
CS (1) CS272766B2 (fr)
DD (1) DD261156A5 (fr)
DE (2) DE3525801A1 (fr)
DK (1) DK157867C (fr)
ES (1) ES2001019A6 (fr)
FI (1) FI89921C (fr)
GR (1) GR861866B (fr)
HU (1) HU198486B (fr)
IE (1) IE59025B1 (fr)
IL (1) IL79457A0 (fr)
LT (1) LT3869B (fr)
LV (1) LV5703A3 (fr)
MA (1) MA20739A1 (fr)
MX (1) MX9254A (fr)
NO (1) NO165803C (fr)
NZ (1) NZ216888A (fr)
OA (1) OA08707A (fr)
PH (1) PH26262A (fr)
PT (1) PT83013B (fr)
RU (1) RU2051918C1 (fr)
TN (1) TNSN86111A1 (fr)
WO (1) WO1987000523A2 (fr)
ZA (1) ZA865374B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2201930C2 (ru) * 1996-06-07 2003-04-10 Авентис Фарма Дойчланд Гмбх Применение производных теофиллина для лечения и профилактики состояний шока, новые соединения ксантина

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
DK0484785T3 (da) * 1990-11-07 1996-09-23 Hoechst Marion Roussel Inc Anvendelse af xanthiner til fremstilling af et lægemiddel, der er virksomt til inhibering af formeringen af humane retrovira
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (fr) * 1991-12-11 1993-07-21 Hoechst Ag
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
ATE230990T1 (de) * 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
EP0570831A2 (fr) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Utilisation de dérivés de Xanthine pour le traitement de dommages cérébraux après interruption de la circulation sanguine
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
EP0739203A4 (fr) * 1994-01-14 2000-12-20 Cell Therapeutics Inc Methode de traitement d'affections dues a la proliferation cellulaire en reponse aux pdgf, egf, fgf et vegf
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
EP0746557A4 (fr) * 1994-02-18 1997-05-02 Cell Therapeutics Inc Mediateurs de signalisation intracellulaire
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
RU2157209C1 (ru) * 2000-03-23 2000-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Улучшающее мозговое кровообращение, антиагрегатное средство и способ его получения
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
WO2003091350A1 (fr) * 2002-04-24 2003-11-06 Basf Coatings Ag Melanges thixotropes thermodurcissables contenant des groupes carbamate et/ou allophanate
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
WO2009108383A2 (fr) * 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Dérivés de xanthine substitués
CN102046631A (zh) * 2008-03-31 2011-05-04 阳光医药工业有限公司 制备吗啡烷类似物的改良方法
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011028835A1 (fr) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Dérivés de xanthine substitués
WO2012031073A1 (fr) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Procédé de préparation d'un alcool secondaire deutéré à enrichissement énantiomérique à partir d'une cétone correspondante sans réduction de l'intégration de deutérium
WO2012031072A1 (fr) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Procédé de préparation d'un alcool secondaire deutéré, enrichi en certains énantiomères, à partir d'une cétone correspondante sans avoir à réduire l'incorporation du deutérium
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
DE2207860A1 (de) * 1972-02-19 1973-08-23 Albert Ag Chem Werke Arzneimittel, insbesondere fuer die durchblutung des gehirns, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese wirkstoffe
FR2236501A2 (fr) * 1973-07-11 1975-02-07 Albert Ag Chem Werke
DE2432702A1 (de) * 1974-07-08 1976-01-29 Hoechst Ag Verfahren zur herstellung von hydroxyalkylxanthinen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
CA1075690A (fr) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Derives de la xanthine
DE3062499D1 (en) * 1979-04-05 1983-05-05 Beecham Wuelfing Gmbh & Co Kg Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE2207860A1 (de) * 1972-02-19 1973-08-23 Albert Ag Chem Werke Arzneimittel, insbesondere fuer die durchblutung des gehirns, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese wirkstoffe
FR2236501A2 (fr) * 1973-07-11 1975-02-07 Albert Ag Chem Werke
DE2432702A1 (de) * 1974-07-08 1976-01-29 Hoechst Ag Verfahren zur herstellung von hydroxyalkylxanthinen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2201930C2 (ru) * 1996-06-07 2003-04-10 Авентис Фарма Дойчланд Гмбх Применение производных теофиллина для лечения и профилактики состояний шока, новые соединения ксантина

Also Published As

Publication number Publication date
FI89921C (fi) 1993-12-10
IE861917L (en) 1987-01-19
DK157867B (da) 1990-02-26
DK139287D0 (da) 1987-03-18
WO1987000523A2 (fr) 1987-01-29
FI89921B (fi) 1993-08-31
DE3671627D1 (de) 1990-07-05
DK157867C (da) 1990-07-30
JPH0788382B2 (ja) 1995-09-27
CN86105835A (zh) 1987-01-14
KR870700623A (ko) 1987-12-30
DD261156A5 (de) 1988-10-19
JPS63501149A (ja) 1988-04-28
LT3869B (en) 1996-04-25
DK139287A (da) 1987-03-18
PT83013B (pt) 1989-01-30
AR244689A1 (es) 1993-11-30
BG60767B2 (bg) 1996-02-29
PT83013A (de) 1986-08-01
TNSN86111A1 (fr) 1990-01-01
GR861866B (en) 1986-11-17
DE3525801A1 (de) 1987-01-22
ZA865374B (en) 1987-02-25
MX9254A (es) 1993-06-01
AU6143986A (en) 1987-02-10
CS272766B2 (en) 1991-02-12
OA08707A (en) 1989-03-31
PH26262A (en) 1992-04-01
IL79457A0 (en) 1986-10-31
KR950001019B1 (ko) 1995-02-07
HUT47274A (en) 1989-02-28
CA1262248A (fr) 1989-10-10
CN1026112C (zh) 1994-10-05
ES2001019A6 (es) 1988-04-16
NZ216888A (en) 1989-05-29
HU198486B (en) 1989-10-30
LTIP1467A (en) 1995-05-25
EP0268585B1 (fr) 1990-05-30
AU588350B2 (en) 1989-09-14
IE59025B1 (en) 1993-12-15
NO165803B (no) 1991-01-02
ATE53211T1 (de) 1990-06-15
FI880174L (fi) 1988-01-15
US4833146A (en) 1989-05-23
CS545386A2 (en) 1990-04-11
NO871111L (no) 1987-03-18
EP0268585A1 (fr) 1988-06-01
MA20739A1 (fr) 1987-04-01
RU2051918C1 (ru) 1996-01-10
NO165803C (no) 1991-04-10
LV5703A3 (lv) 1995-02-20
FI880174A0 (fi) 1988-01-15
NO871111D0 (no) 1987-03-18

Similar Documents

Publication Publication Date Title
WO1987000523A3 (fr) Hydroxyalkylxanthines tertiaires, leur procede de fabrication, medicaments les contenant et leur utilisation
IL77222A (en) Substituted 15,19-epoxy-3h-pyrido-(and pyrrolo)-(2,1-c)(1,4)-oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrones,their production and pharmaceutical compositions containing the same
ATE60579T1 (de) Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten.
DE3170504D1 (en) Piperidylidene derivatives, their production and pharmaceutical compositions containing them
AU6235890A (en) Purification of 1,1-dichloro-1-fluoroethane
PT72574B (en) Process for the preparation of 1,1-diphenyl-2-(1,2,4-triazol-1--yl)ethanols and of pharmaceutical compositions containing them
MY102003A (en) Novel derivatives of 4, 5-dihydrooxazoles, a process for their preparation, and their use.
IN160952B (fr)
ZA874541B (en) Removal of impurities from hydrocarbon by catalystic hydrogenation("hytrofining")and additive for use therewith
DE3371909D1 (en) 7-alpha-acylthio-15,16-methylene-3-oxo-17-alpha-pregna-1,4-diene-21,17-carbolactones, their preparation and use as medicinal agents
HU9300476D0 (en) Method for producing pharmaceutical preparatives containing xanthine derivatives
ZA872276B (en) Pharmaceutical compositions containing 5-phenyl-1,3-dioxoalkenyl compounds
HUT58273A (en) Process for producing aminoketon compounds and pharmaceutical compositions containing them
JPS57108087A (en) (4,5)-4h-benzo(1,2-b)cycloheptafuran derivative, manufacture and use as medicine
JPS5262207A (en) Purification process for chloroform
JPS52108992A (en) Purification of cefalexin
UA41309C2 (uk) ПОХІДНІ 11-<font face="Symbol">b</font>-БЕНЗАЛЬДОКСИМЕСТРА-4,9-ДІЄНУ, СПОСІБ ЇХ ОТРИМАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
DE3371633D1 (en) A process for preparing oxanosine
ES478072A1 (es) Un procedimiento de preparacion de 2-metoxi-benzamidas.
FR2515040B1 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI HU JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI HU JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1986904158

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 880174

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1986904158

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1986904158

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 880174

Country of ref document: FI